Compare RNST & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | BLTE |
|---|---|---|
| Founded | 1904 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | N/A | 2022 |
| Metric | RNST | BLTE |
|---|---|---|
| Price | $41.19 | $176.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $42.25 | ★ $161.57 |
| AVG Volume (30 Days) | ★ 744.6K | 232.2K |
| Earning Date | 01-27-2026 | 03-16-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $878,392,000.00 | N/A |
| Revenue This Year | $31.72 | N/A |
| Revenue Next Year | $4.58 | N/A |
| P/E Ratio | $19.96 | ★ N/A |
| Revenue Growth | ★ 24.32 | N/A |
| 52 Week Low | $26.97 | $49.00 |
| 52 Week High | $42.11 | $200.00 |
| Indicator | RNST | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 69.93 | 58.49 |
| Support Level | $37.31 | $175.18 |
| Resistance Level | $42.11 | $192.94 |
| Average True Range (ATR) | 1.17 | 11.13 |
| MACD | 0.38 | 0.89 |
| Stochastic Oscillator | 85.38 | 48.27 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.